Filing Flows › Integra Lifesciences Holdings (IART) › Q2 2026 › vs Q2 2025
Integra Lifesciences Holdings (IART) Q2 2026 vs Q2 2025 (year over year)
Integra Lifesciences Holdings's revenue rose $3.2M (+0.8%) from $416M in Q2 2025 to $419M in Q2 2026. The biggest changes: Specialty Surgery +$5.3M (+2%); Tissue Reconstruction −$2.2M (-2%). Operating margin 4.6% against -123.4% (+128.0 pts).
Integra Lifesciences Holdings, Q2 2026: revenue $419M (+0.8% year over year), operating margin 4.6%, net earnings $4.5M, operating cash flow $22.8M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 4.6% | -123.4% | +128.0 pts |
| Net margin | 1.1% | -116.5% | +117.5 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Specialty Surgery | $309M | $304M | $5.3M | +2% |
| Tissue Reconstruction | $109M | $112M | −$2.2M | -2% |
| Revenue | $419M | $416M | $3.2M | +0.8% |
| Operating profit | $19.3M | −$513M | $532M | — |
| Costs & expenses | $399M | $928M | −$529M | -57% |
| Pre-tax earnings | $4.7M | −$531M | $536M | — |
| Other expense, net | $14.5M | $18.3M | −$3.7M | -20% |
| Cost of revenue | $199M | $206M | −$7.3M | -4% |
| Research & development | $24.3M | $27.0M | −$2.7M | -10% |
| SG&A | $172M | $180M | −$7.5M | -4% |
| Other operating costs | $3.8M | $515M | −$511M | -99% |
| Net earnings | $4.5M | −$484M | $489M | — |
| Income tax | $262K | −$46.9M | $47.1M | — |
| Share-based compensation | $5.8M | $5.3M | $549K | +10% |
| Working capital & other | $12.5M | $488M | −$475M | -97% |
| Operating cash flow | $22.8M | $8.9M | $13.9M | +156% |
Questions
How much did Integra Lifesciences Holdings's revenue grow year over year in Q2 2026?
Integra Lifesciences Holdings's revenue rose $3.2M (+0.8%) from $416M in Q2 2025 to $419M in Q2 2026.
What drove Integra Lifesciences Holdings's revenue change in Q2 2026?
Specialty Surgery +$5.3M (+2%); Tissue Reconstruction −$2.2M (-2%).